Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC

Blocking Periostin Prevents Metastasis in a Mouse Cancer Model

By BiotechDaily International staff writers
Posted on 22 Dec 2011
Cancer researchers have identified a protein that seems to be required for cancer cells to metastasize successfully and established secondary tumors at sites distantly removed from the original primary tumor.

Metastatic growth in distant organs is the major cause of cancer mortality, yet this process is inefficient for many cancer types and is accomplished only by a minority of cancer cells that reach distant sites.

Investigators at the Swiss Center for Experimental Cancer Research (Lausanne, Switzerland) worked with a mouse model to look for molecular keys that could enhance a tumor's ability to establish secondary tumors successfully.

They reported in the December 7, 2011, online edition of the journal Nature that a small population of cancer stem cells was critical for metastatic colonization, and that stromal niche signals expressed by potential sites of colonization were crucial to the expansion process. They found that the protein periostin (POSTN), a component of the extracellular matrix, was expressed by fibroblasts in normal tissue and in the stroma of the primary tumor. Infiltrating tumor cells needed to induce stromal POSTN expression in the secondary target organ to initiate colonization. POSTN was required to allow cancer stem cell maintenance, and blocking its function prevented metastasis.

The investigators showed that several conditions were necessary for cancer to propagate. "In particular, we were able to isolate a protein, periostin, in the niches where metastases develop," said senior author Dr. Joerg Huelsken, professor of molecular oncology at the Swiss Center for Experimental Cancer. "Without this protein, the cancer stem cell cannot initiate metastasis; instead, it disappears or remains dormant."

Experimental treatments that blocked periostin activity produced very few side effects in mice, but the investigators caution that this does not necessarily mean the same will hold true in humans.

Related Links:
Swiss Center for Experimental Cancer Research



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.